VIB VERMOEGEN AG (VIH1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:VIH1 - DE000A2YPDD0 - Common Stock
10.1 EUR
0 (0%)
We assign a fundamental rating of 5 out of 10 to VIH1. VIH1 was compared to 75 industry peers in the Real Estate Management & Development industry. There are concerns on the financial health of VIH1 while its profitability can be described as average. VIH1 is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year VIH1 was profitable.
In the past year VIH1 had a positive cash flow from operations.
VIH1 had positive earnings in each of the past 5 years.
VIH1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
VIH1 has a Return On Assets (1.69%) which is comparable to the rest of the industry.
VIH1's Return On Equity of 3.99% is fine compared to the rest of the industry. VIH1 outperforms 61.33% of its industry peers.
VIH1 has a Return On Invested Capital of 3.21%. This is in the better half of the industry: VIH1 outperforms 68.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for VIH1 is in line with the industry average of 3.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROIC | 3.21% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
1.3 Margins
VIH1 has a Profit Margin of 34.63%. This is in the better half of the industry: VIH1 outperforms 74.67% of its industry peers.
In the last couple of years the Profit Margin of VIH1 has declined.
With an excellent Operating Margin value of 70.15%, VIH1 belongs to the best of the industry, outperforming 90.67% of the companies in the same industry.
In the last couple of years the Operating Margin of VIH1 has declined.
Looking at the Gross Margin, with a value of 78.88%, VIH1 is in the better half of the industry, outperforming 69.33% of the companies in the same industry.
In the last couple of years the Gross Margin of VIH1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% |
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VIH1 is destroying value.
The number of shares outstanding for VIH1 remains at a similar level compared to 1 year ago.
VIH1 has more shares outstanding than it did 5 years ago.
VIH1 has a better debt/assets ratio than last year.
2.2 Solvency
VIH1 has an Altman-Z score of 0.70. This is a bad value and indicates that VIH1 is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VIH1 (0.70) is worse than 64.00% of its industry peers.
The Debt to FCF ratio of VIH1 is 10.39, which is on the high side as it means it would take VIH1, 10.39 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 10.39, VIH1 is doing good in the industry, outperforming 74.67% of the companies in the same industry.
A Debt/Equity ratio of 1.01 is on the high side and indicates that VIH1 has dependencies on debt financing.
With a Debt to Equity ratio value of 1.01, VIH1 perfoms like the industry average, outperforming 44.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Altman-Z | 0.7 |
ROIC/WACC0.73
WACC4.38%
2.3 Liquidity
VIH1 has a Current Ratio of 1.03. This is a normal value and indicates that VIH1 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.03, VIH1 is in line with its industry, outperforming 44.00% of the companies in the same industry.
A Quick Ratio of 1.03 indicates that VIH1 should not have too much problems paying its short term obligations.
VIH1 has a Quick ratio of 1.03. This is in the better half of the industry: VIH1 outperforms 61.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The earnings per share for VIH1 have decreased strongly by -72.11% in the last year.
Measured over the past years, VIH1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.74% on average per year.
VIH1 shows a small growth in Revenue. In the last year, the Revenue has grown by 4.50%.
VIH1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.78% yearly.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
3.2 Future
VIH1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.54% yearly.
VIH1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.81% yearly.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 9.27 indicates a reasonable valuation of VIH1.
Based on the Price/Earnings ratio, VIH1 is valued a bit cheaper than 80.00% of the companies in the same industry.
VIH1's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
VIH1 is valuated cheaply with a Price/Forward Earnings ratio of 4.63.
VIH1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VIH1 is cheaper than 97.33% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.88. VIH1 is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.27 | ||
| Fwd PE | 4.63 |
4.2 Price Multiples
94.67% of the companies in the same industry are more expensive than VIH1, based on the Enterprise Value to EBITDA ratio.
VIH1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VIH1 is cheaper than 89.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.36 | ||
| EV/EBITDA | 6.32 |
4.3 Compensation for Growth
VIH1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VIH1 may justify a higher PE ratio.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.39%, VIH1 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 4.22, VIH1 has a dividend in line with its industry peers.
With a Dividend Yield of 0.39, VIH1 pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
FRA:VIH1 (1/9/2026, 11:33:51 AM)
10.1
0 (0%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)
Earnings (Next)
Inst Owners0.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap333.80M
Revenue(TTM)104.37M
Net Income(TTM)36.14M
Analysts82.86
Price Target11.73 (16.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.27 | ||
| Fwd PE | 4.63 | ||
| P/S | 3.2 | ||
| P/FCF | 3.36 | ||
| P/OCF | 3.36 | ||
| P/B | 0.37 | ||
| P/tB | 0.38 | ||
| EV/EBITDA | 6.32 |
EPS(TTM)1.09
EY10.79%
EPS(NY)2.18
Fwd EY21.61%
FCF(TTM)3.01
FCFY29.76%
OCF(TTM)3.01
OCFY29.76%
SpS3.16
BVpS27.39
TBVpS26.47
PEG (NY)0.89
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.69% | ||
| ROE | 3.99% | ||
| ROCE | 3.73% | ||
| ROIC | 3.21% | ||
| ROICexc | 3.25% | ||
| ROICexgc | 3.3% | ||
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% | ||
| FCFM | 95.17% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexgc growth 3Y-10.75%
ROICexgc growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.01 | ||
| Debt/FCF | 10.39 | ||
| Debt/EBITDA | 4.3 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 46.63% | ||
| Profit Quality | 274.83% | ||
| Current Ratio | 1.03 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 0.7 |
F-Score4
WACC4.38%
ROIC/WACC0.73
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%15.94%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%26.78%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%
VIB VERMOEGEN AG / VIH1.DE FAQ
What is the fundamental rating for VIH1 stock?
ChartMill assigns a fundamental rating of 5 / 10 to VIH1.DE.
Can you provide the valuation status for VIB VERMOEGEN AG?
ChartMill assigns a valuation rating of 8 / 10 to VIB VERMOEGEN AG (VIH1.DE). This can be considered as Undervalued.
What is the profitability of VIH1 stock?
VIB VERMOEGEN AG (VIH1.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for VIH1 stock?
The financial health rating of VIB VERMOEGEN AG (VIH1.DE) is 3 / 10.